SOSV

Pear Bio uses organ-on-a-chip and computer vision technology to recreate, visualize, and compute the human tumor microenvironment and its effects on cancer progression. The company was founded in 2017 and is headquartered in London.

Our first product, HaloFilm turns any surface into an antimicrobial surface by holding chlorine from store-bought disinfectants on surfaces in a safe and effective manner for as long as a month. HaloFilm contains a novel polymer that when sprayed on creates a thin transparent film that binds to the surface and to chlorine, at levels equivalent to what you would find in a pool. Chlorine is a universally used as a disinfectant against bacteria, virus and fungi, but has a short effective life. We extend the lifetime and overall utility of chlorine to protect surfaces continuously. Our focus is on high touch surfaces in hospitals, mass transit systems, schools, and more; wherever pathogens spread and endanger human health.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Provider of textile waste management technology intended to solve the problem of textile waste with a patented method. The company initiates and implements circular economy projects, training, and international cooperation programs, enabling users to use smart collection, separation, and low-cost upcycling of large volumes of low-value textile waste.

Pear Bio uses organ-on-a-chip and computer vision technology to recreate, visualize, and compute the human tumor microenvironment and its effects on cancer progression. The company was founded in 2017 and is headquartered in London.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Mirá Biotech is a biotechnology company focused on the development of sustainable, formaldehyde-free engineered wood products. By utilizing waste materials, such as sugar cane bagasse, the company aims to create all-natural alternatives to traditional wood boards, thereby promoting a circular economy. This innovative approach not only eliminates the need for tree harvesting but also contributes to sustainable industrial practices, positioning Mirá Biotech as a leader in environmentally friendly manufacturing solutions.

Samphire Neuroscience is a neurotechnology company based in London, England, founded in 2021. The company focuses on women's health and lifestyle enhancement through innovative solutions. Its primary product is a headband device that employs non-invasive electrical neuromodulation to stimulate specific areas of the brain. This technology aims to alleviate symptoms commonly associated with menstrual cycles, including pain, fatigue, and mood disturbances, thereby improving the overall well-being of women.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

Aksense is an innovative company focused on developing affordable and portable nucleic acid-based diagnostic panels for the rapid and accurate detection of pathogens. Its flagship product is the first portable rapid infection diagnostic biosensor designed to improve healthcare quality and safety. By facilitating early detection and treatment of infections, Aksense's technology aims to enhance antibiotic prescribing practices and reduce the spread of infections. This approach not only improves patient outcomes but also supports public health initiatives by allowing users to recover faster through cost-effective molecular testing solutions.

Neptune Robotics develops and manufactures underwater drones designed for enterprises in the maritime industry. Its underwater drones reduce the spread of invasive species in the ocean and also include filtration and debris collection systems designed to clean up oceans, enabling the reduction of waste in the oceans and improve ocean ecosystems.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical products aimed at controlling challenging crop diseases, pests, and weeds. Utilizing patented protein evolution technology, the company has created a peptide and RNA interference (RNAi) delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform allows for advanced protein engineering through continuous laboratory evolution and other methods, such as phage display. This technology enhances researchers' capabilities in control, reporting, recording, simulation, and remote access, positioning Innatrix as a leader in sustainable agricultural solutions.

Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical products aimed at controlling challenging crop diseases, pests, and weeds. Utilizing patented protein evolution technology, the company has created a peptide and RNA interference (RNAi) delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform allows for advanced protein engineering through continuous laboratory evolution and other methods, such as phage display. This technology enhances researchers' capabilities in control, reporting, recording, simulation, and remote access, positioning Innatrix as a leader in sustainable agricultural solutions.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, that specializes in the production of natural soluble melanin through precision fermentation technology. This innovative approach allows the company to manufacture melanin at scale and at an affordable cost, ensuring high purity and ease of application across various industries. Avisa Myko's melanin serves multiple purposes, including protection against ionizing radiation and electricity generation, and is utilized in cosmetics, biomedicine, organic semiconductors, biosensors, and textiles. The company is also developing a prototype sunscreen that leverages its melanin as an ultraviolet blocker without relying on conventional chemical or mineral filters. Through its patented technology, Avisa Myko aims to improve human health and environmental sustainability by integrating melanin into products such as latex, fabrics, and laminated materials.

NovoNutrients is focused on converting industrial waste carbon dioxide emissions into high-value protein ingredients for food and animal feed. The company has developed a fermentation platform that utilizes proprietary microbes and advanced gas fermentation systems to transform CO2, along with hydrogen and oxygen, into complete and safe single-cell protein. This innovative approach not only provides sustainable protein sources to support a growing population but also plays a role in combating climate change through carbon capture and utilization. By addressing both food security and environmental sustainability, NovoNutrients aims to meet the increasing demand for alternative protein solutions.

PONS is a company specializing in the development of artificial intelligence to enhance ultrasound imaging, particularly for brain diagnostics. Utilizing machine learning algorithms, PONS transforms traditional ultrasound systems into smart, AI-driven diagnostic tools that improve scan resolution, tissue contrast, and noise reduction. This innovation aims to provide expert-level insights without the need for costly new hardware. The company's primary objective is to create a wearable ultrasound device to assist first responders and ambulance doctors with pre-diagnostics in challenging circumstances, facilitating early disease detection and preventive screening. By focusing on important anatomical features in ultrasound scans, PONS seeks to advance the capabilities of ultrasound technology in neurosurgery and related fields.

At NAT4Bio, we develop naturally-sourced coatings that protect produce from spoilage and decay. By leveraging microbial fermentation of selected fungi & bacteria and through carefully designed downstream processes, we obtain cell-free compounds, meaning we use microbes' active principles without the microbes themselves. Our first product is a natural and edible coating for fresh lemons that could potentially replace the combination of waxes and chemical fungicides. We are also prototyping formulations for blueberries and avocados, and we aim to expand our portfolio to address the needs of every fruit class.

ArgenTAG specializes in developing synthetic DNA barcoding technology aimed at enhancing the capabilities of long-read sequencing applications in genomics. By addressing the limitations associated with reduced multiplexing capacity and sequencing throughput, ArgenTAG enables the simultaneous analysis of thousands of samples. The company integrates advanced micro-fabrication techniques with next-generation DNA sequencing and molecular biology, leveraging reengineered error correction technologies initially derived from digital communications. This innovative approach facilitates the decentralization of genome sequencing, allowing medical professionals to effectively analyze antibodies and perform single-cell sequencing, thus advancing the field of personalized medicine.

At NAT4Bio, we develop naturally-sourced coatings that protect produce from spoilage and decay. By leveraging microbial fermentation of selected fungi & bacteria and through carefully designed downstream processes, we obtain cell-free compounds, meaning we use microbes' active principles without the microbes themselves. Our first product is a natural and edible coating for fresh lemons that could potentially replace the combination of waxes and chemical fungicides. We are also prototyping formulations for blueberries and avocados, and we aim to expand our portfolio to address the needs of every fruit class.

ArgenTAG specializes in developing synthetic DNA barcoding technology aimed at enhancing the capabilities of long-read sequencing applications in genomics. By addressing the limitations associated with reduced multiplexing capacity and sequencing throughput, ArgenTAG enables the simultaneous analysis of thousands of samples. The company integrates advanced micro-fabrication techniques with next-generation DNA sequencing and molecular biology, leveraging reengineered error correction technologies initially derived from digital communications. This innovative approach facilitates the decentralization of genome sequencing, allowing medical professionals to effectively analyze antibodies and perform single-cell sequencing, thus advancing the field of personalized medicine.

Sóliome is a biotechnology company founded in 2021 and based in San Francisco, California. The company specializes in developing protein-based sunscreens designed to be safe for both the skin and the environment. These innovative products aim to reduce inflammation and skin damage caused by traditional sunscreens, which often contain harmful xenobiotic ingredients that can absorb into the skin and contribute to ecological harm. Sóliome's approach allows customers to protect their skin from harmful rays without the adverse effects associated with conventional sunscreen formulations.

Sóliome is a biotechnology company founded in 2021 and based in San Francisco, California. The company specializes in developing protein-based sunscreens designed to be safe for both the skin and the environment. These innovative products aim to reduce inflammation and skin damage caused by traditional sunscreens, which often contain harmful xenobiotic ingredients that can absorb into the skin and contribute to ecological harm. Sóliome's approach allows customers to protect their skin from harmful rays without the adverse effects associated with conventional sunscreen formulations.

Inso Biosciences is an early-stage biotechnology company based in Ithaca, New York, affiliated with Cornell University. The company focuses on developing innovative platform technology for biological sample processing, specifically designed for genomic analysis, including DNA sequencing. Utilizing advanced microfluidic technology, Inso Biosciences aims to revolutionize sample processing by efficiently separating and isolating cellular components. This technology enables healthcare and biotechnology companies to enhance their biological sample preparation capabilities, facilitating more effective research and analysis in the field of genomics.

Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.

Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.

VemiCo is a biotechnology company focused on extending healthy living by addressing the aging process. It utilizes artificial intelligence and synthetic biology to identify and develop promising molecules derived from gut microbial DNA. This innovative approach allows medical professionals to leverage the benefits of microbiomes, promoting gut health and enhancing overall well-being.

Valanx Biotech GmbH, founded in 2017 and based in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company focuses on creating SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with therapeutic agents to produce antibody-drug conjugates for cancer treatment. This technology also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Valanx Biotech offers bioanalytics and mass spectrometry services to meet specific client needs, enhancing the efficiency and effectiveness of protein-drug conjugate development.

Samphire Neuroscience is a neurotechnology company based in London, England, founded in 2021. The company focuses on women's health and lifestyle enhancement through innovative solutions. Its primary product is a headband device that employs non-invasive electrical neuromodulation to stimulate specific areas of the brain. This technology aims to alleviate symptoms commonly associated with menstrual cycles, including pain, fatigue, and mood disturbances, thereby improving the overall well-being of women.

Gaia Laboratories revolutionizes cell production, creating powerful solutions for the defining challenges of time. The founding principles behind Gaia Laboratories are to combat climate change, enable space-food, and make cell therapy accessible to everyone.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

Verdex Technologies Inc. specializes in designing, patenting, and licensing non-toxic nanofiber production equipment for filtration and biomedical applications. The company’s innovative technology allows for the functionalization of nanofibers by incorporating nano-sized ingredients, which enhances the effectiveness of various products, including water filters that can eliminate challenging contaminants. Based in North Chesterfield, Virginia, Verdex Technologies emphasizes the use of biodegradable and bioresorbable polymers, avoiding harmful solvents and petroleum products in its processes. Founded by Rex B. Kirby, Jr., the company prides itself on its agile structure, integrity, and exceptional service, focusing on client needs and safety while maintaining high standards of quality. Verdex Technologies is financially robust, with substantial bonding capacity, positioning itself as a reliable partner in the nanofiber technology sector.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

PunaBio is a Buenos Aires-based company that develops biological products aimed at enhancing agricultural productivity through environmentally friendly methods. By utilizing extremophile microorganisms, PunaBio focuses on improving crop nutrition, which contributes to increased yields and better crop quality. Their products are designed to enable farmers to cultivate crops on degraded soils and restore and enrich agricultural land sustainably. This approach not only helps improve farmers' productivity but also promotes sustainable agricultural practices.

Pear Bio uses organ-on-a-chip and computer vision technology to recreate, visualize, and compute the human tumor microenvironment and its effects on cancer progression. The company was founded in 2017 and is headquartered in London.

Inso Biosciences is an early-stage biotechnology company based in Ithaca, New York, affiliated with Cornell University. The company focuses on developing innovative platform technology for biological sample processing, specifically designed for genomic analysis, including DNA sequencing. Utilizing advanced microfluidic technology, Inso Biosciences aims to revolutionize sample processing by efficiently separating and isolating cellular components. This technology enables healthcare and biotechnology companies to enhance their biological sample preparation capabilities, facilitating more effective research and analysis in the field of genomics.

Inso Biosciences is an early-stage biotechnology company based in Ithaca, New York, affiliated with Cornell University. The company focuses on developing innovative platform technology for biological sample processing, specifically designed for genomic analysis, including DNA sequencing. Utilizing advanced microfluidic technology, Inso Biosciences aims to revolutionize sample processing by efficiently separating and isolating cellular components. This technology enables healthcare and biotechnology companies to enhance their biological sample preparation capabilities, facilitating more effective research and analysis in the field of genomics.

Kutanios is a biotechnology firm focused on creating new compounds for anti-aging, sun care, anti-acne, and skin cleaning items. Headwuartered in London.

Kutanios is a biotechnology firm focused on creating new compounds for anti-aging, sun care, anti-acne, and skin cleaning items. Headwuartered in London.

Neptune Robotics develops and manufactures underwater drones designed for enterprises in the maritime industry. Its underwater drones reduce the spread of invasive species in the ocean and also include filtration and debris collection systems designed to clean up oceans, enabling the reduction of waste in the oceans and improve ocean ecosystems.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Verdex Technologies Inc. specializes in designing, patenting, and licensing non-toxic nanofiber production equipment for filtration and biomedical applications. The company’s innovative technology allows for the functionalization of nanofibers by incorporating nano-sized ingredients, which enhances the effectiveness of various products, including water filters that can eliminate challenging contaminants. Based in North Chesterfield, Virginia, Verdex Technologies emphasizes the use of biodegradable and bioresorbable polymers, avoiding harmful solvents and petroleum products in its processes. Founded by Rex B. Kirby, Jr., the company prides itself on its agile structure, integrity, and exceptional service, focusing on client needs and safety while maintaining high standards of quality. Verdex Technologies is financially robust, with substantial bonding capacity, positioning itself as a reliable partner in the nanofiber technology sector.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

QuantumCyte, Inc. is a biotechnology company based in Sunnyvale, California, founded in 2014. It specializes in developing a cell analysis system designed to enhance drug efficacy predictions and advance cancer research. By analyzing large numbers of cells, QuantumCyte aims to deepen the understanding of immune system and cancer biology. The company utilizes artificial intelligence in its pathology technology platform to provide precise cellular data, facilitating single-cell analysis for healthcare providers. Its team comprises experts from various fields, including biology, high technology, and diagnostics, with backgrounds in esteemed organizations such as Stanford and Genentech. QuantumCyte has established strong collaborations with specialists in cancer and genomic sequencing to meet fundamental research needs and ensure the scalability of its products.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

CyGenica specializes in developing innovative delivery solutions for drugs, gene editing components, and antibiotics using a non-viral, non-toxic platform. The company focuses on creating molecular devices that facilitate the programmable delivery of anticancer drugs and other therapeutic agents directly into cells. These devices are designed to cross cellular membrane barriers, allowing for the effective transport of functional molecules into the cytoplasm and various cellular organelles. By enabling pharmaceutical and biotechnology companies to develop new types of anticancer drugs with extended brand lifecycles, CyGenica aims to enhance the efficacy and safety of medical treatments.

Neurode makes non-invasive wearable devices that improve cognitive performance for people with neurological conditions. The company's wearable device, Neurode Wave, is a headset that is a drug-free treatment that uses non-invasive electrical stimulation to balance the underactivity present in ADHD brains. Using it in short daily sessions in combination with the company's paired app provides lasting improvements in symptoms like working memory, attention, and impulse control. The Neurode app is designed to be paired with the device. Paired activities are used in conjunction with the headset to improve performance in tasks requiring the use of executive functions. The app also works separately from the device as an all-in-one ADHD management plan. It has checklists and reminders for forgetful users, custom alarms developed by clinicians to help develop self-awareness, and trackers for a healthy diet and exercise. The company was founded in Sydney, New South Wales in 2021.

Our first product, HaloFilm turns any surface into an antimicrobial surface by holding chlorine from store-bought disinfectants on surfaces in a safe and effective manner for as long as a month. HaloFilm contains a novel polymer that when sprayed on creates a thin transparent film that binds to the surface and to chlorine, at levels equivalent to what you would find in a pool. Chlorine is a universally used as a disinfectant against bacteria, virus and fungi, but has a short effective life. We extend the lifetime and overall utility of chlorine to protect surfaces continuously. Our focus is on high touch surfaces in hospitals, mass transit systems, schools, and more; wherever pathogens spread and endanger human health.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

KOLIBRI is an early-stage deep-tech biotech start-up company that unlocks the potential of gene therapies and next-generation vaccines. It aims to make large-scale viral vector manufacturing cheaper and faster by combining cutting-edge techniques in chemical optimization and acoustics. The company was founded n 2020.

Neurocess specializes in wearable technology designed to enhance training performance and minimize injury risks for professional athletes. The company develops attachable sensors that monitor muscle activity during training sessions. These sensors capture critical data on muscle balance, contraction rates, fatigue levels, injury risks, and dehydration. By providing this valuable information, Neurocess enables coaches and athletes to optimize training efficiency and implement preventative measures against injuries.

Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.

Developer of a real-time hydration biosensor platform designed to monitor human bodies at a molecular level. The company's platform is a wearable, non-invasive patch that captures an athlete's sweat and interprets key bio-markers in real-time, starting with electrolytes and total body fluid loss, enabling users to get personalized recommendations that help them improve their performance.

Gaia Laboratories revolutionizes cell production, creating powerful solutions for the defining challenges of time. The founding principles behind Gaia Laboratories are to combat climate change, enable space-food, and make cell therapy accessible to everyone.

Nordetect IVS is a biochemical analysis company based in Copenhagen, Denmark, specializing in the development of biosensors and microfluidic chip technology for precision agriculture. Founded in 2016, the company focuses on nutrient analysis by detecting and quantifying essential macronutrients such as nitrogen, phosphorus, and potassium in soil. Its Lab-on-a-chip devices facilitate reliable and affordable nutrient testing, enabling agronomists and farm-service companies to deliver actionable insights to farmers regarding soil health. By providing results on the nutritional content of soil and recommendations for fertilizer application, Nordetect helps optimize crop performance and supports informed agricultural practices.

Developer of a portable neuroimaging system designed to track and predict recovery of movement function during the rehabilitation of hemiparesis. The company's systems utilize a proprietary optical imaging system, assessment software, and data analytics to measure neural biomarkers and aid neurological rehabilitation, enabling therapists to make sustainable treatment decisions.

Developing technology to fight mosquitoes with mosquitoes.

Proteinea is a biotechnology company that focuses on insect-based solutions, specifically utilizing the Black Soldier Fly as a mini-biofactory. By integrating biological science with engineering and molecular techniques, the company aims to reduce the capital and operational costs typically associated with conventional bioreactors. Additionally, Proteinea has developed a protein engineering platform that leverages proprietary artificial intelligence models and computational tools to design next-generation antibodies. This platform enhances the efficacy, safety, and convenience of biologics for antibody medicines, allowing clients to access advanced biologic designs tailored for therapeutic applications. Through these innovative approaches, Proteinea seeks to advance the fields of biotechnology and protein engineering.

Proteinea is a biotechnology company that focuses on insect-based solutions, specifically utilizing the Black Soldier Fly as a mini-biofactory. By integrating biological science with engineering and molecular techniques, the company aims to reduce the capital and operational costs typically associated with conventional bioreactors. Additionally, Proteinea has developed a protein engineering platform that leverages proprietary artificial intelligence models and computational tools to design next-generation antibodies. This platform enhances the efficacy, safety, and convenience of biologics for antibody medicines, allowing clients to access advanced biologic designs tailored for therapeutic applications. Through these innovative approaches, Proteinea seeks to advance the fields of biotechnology and protein engineering.

Huue, formerly known as Tinctorium Inc., is a biotechnology company based in Berkeley, California, specializing in sustainable indigo dyeing solutions for the textile and fashion industry. Founded in 2018, the company utilizes a unique technology that mimics natural plant processes within microbes to produce indigo dye. This innovative approach significantly reduces chemical usage in the denim supply chain, offering an environmentally friendly alternative for denim production. By harnessing the power of biotechnology, Huue aims to provide the fashion industry with sustainable coloring options that rely on renewable resources, contributing to a more eco-conscious approach in textile manufacturing.

Huue, formerly known as Tinctorium Inc., is a biotechnology company based in Berkeley, California, specializing in sustainable indigo dyeing solutions for the textile and fashion industry. Founded in 2018, the company utilizes a unique technology that mimics natural plant processes within microbes to produce indigo dye. This innovative approach significantly reduces chemical usage in the denim supply chain, offering an environmentally friendly alternative for denim production. By harnessing the power of biotechnology, Huue aims to provide the fashion industry with sustainable coloring options that rely on renewable resources, contributing to a more eco-conscious approach in textile manufacturing.

NovoNutrients is focused on converting industrial waste carbon dioxide emissions into high-value protein ingredients for food and animal feed. The company has developed a fermentation platform that utilizes proprietary microbes and advanced gas fermentation systems to transform CO2, along with hydrogen and oxygen, into complete and safe single-cell protein. This innovative approach not only provides sustainable protein sources to support a growing population but also plays a role in combating climate change through carbon capture and utilization. By addressing both food security and environmental sustainability, NovoNutrients aims to meet the increasing demand for alternative protein solutions.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Panacea Longevity is a biotechnology company aiming to replicate the health benefits of fasting. The company patent-pending fasting mimetic forumuation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast, enabling customers to have anti-inflammatory and antioxidant effects in human cells that could combat age-associated chronic inflammation and cellular damage. Panacea Longevity was established in 2020 and is based in San Francisco, CA.

Panacea Longevity is a biotechnology company aiming to replicate the health benefits of fasting. The company patent-pending fasting mimetic forumuation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast, enabling customers to have anti-inflammatory and antioxidant effects in human cells that could combat age-associated chronic inflammation and cellular damage. Panacea Longevity was established in 2020 and is based in San Francisco, CA.

Preemadonna is the maker of Nailbot, a patented nail robot and intelligent manicure product line disrupting the $15B nail care industry. Our first Nailbot prints art and photos directly on fingernails in 5 seconds. Future Nailbots print full polish. Nailbot is powered by our art marketplace and community of makers who crave instant self expression, design digital art and love printing on the go with Nailbot. We will build other creative expression on demand printing and robotics products for our Preemadonna customer throughout her/his lifespan.

Nordetect IVS is a biochemical analysis company based in Copenhagen, Denmark, specializing in the development of biosensors and microfluidic chip technology for precision agriculture. Founded in 2016, the company focuses on nutrient analysis by detecting and quantifying essential macronutrients such as nitrogen, phosphorus, and potassium in soil. Its Lab-on-a-chip devices facilitate reliable and affordable nutrient testing, enabling agronomists and farm-service companies to deliver actionable insights to farmers regarding soil health. By providing results on the nutritional content of soil and recommendations for fertilizer application, Nordetect helps optimize crop performance and supports informed agricultural practices.

Developer of a real-time hydration biosensor platform designed to monitor human bodies at a molecular level. The company's platform is a wearable, non-invasive patch that captures an athlete's sweat and interprets key bio-markers in real-time, starting with electrolytes and total body fluid loss, enabling users to get personalized recommendations that help them improve their performance.

Chinova Bioworks Inc. specializes in developing natural antimicrobials for the beverage industry, focusing on enhancing the shelf life of fresh juices. Founded in 2016 and based in Fredericton, Canada, the company utilizes a chitosan polymer derived from fungal-sourced technology, specifically natural fibers from mushrooms. This broad-spectrum preservative effectively protects products from spoilage while remaining a healthy, natural ingredient suitable for use in foods, beverages, cosmetics, and personal care items. By providing manufacturers with a solution to improve product quality and freshness, Chinova Bioworks aims to increase consumer satisfaction and reduce food waste.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Magellan Life Sciences Ltd. is a synthetic biology company based in London, United Kingdom, established in 2018. The company specializes in developing proprietary protein engineering and expression platforms to create innovative plant-inspired proteins, such as brazzein, for applications in the food and beverage industries. Additionally, Magellan Life Sciences offers the XSeed platform, which leverages synthetic biology to advance the development of novel proteins aimed at enhancing the food, health, and nutrition sectors.

Bucha Bio creates a novel biomaterial grown from infinitely renewable bacterial-nanocellulose. Strands of natural fibers interlock to form a high-performance textile with a luxuriously soft handfeel. Produced in weeks rather than months or years, use it in premium applications instead of animal leather, polyurethane, latex, vinyl, and so much more. Creating a reliable material is our goal, adding plastics and petrochemicals like PU polyurethane would make it easy, but we’ve never taken the easy way out. Committed to sustainability, Bucha Bio’s team is dedicated to creating a completely biodegradable textile that enables the next generation of designers to create products for a more sustainable future. Our biomaterial is water-resistant, scratch-resistant, sunlight-resistant, flame-resistant, and so many more reasons to test it out in your next product.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

Bucha Bio creates a novel biomaterial grown from infinitely renewable bacterial-nanocellulose. Strands of natural fibers interlock to form a high-performance textile with a luxuriously soft handfeel. Produced in weeks rather than months or years, use it in premium applications instead of animal leather, polyurethane, latex, vinyl, and so much more. Creating a reliable material is our goal, adding plastics and petrochemicals like PU polyurethane would make it easy, but we’ve never taken the easy way out. Committed to sustainability, Bucha Bio’s team is dedicated to creating a completely biodegradable textile that enables the next generation of designers to create products for a more sustainable future. Our biomaterial is water-resistant, scratch-resistant, sunlight-resistant, flame-resistant, and so many more reasons to test it out in your next product.

Kraken Sense develops an automated pathogen detection platform that includes sensors to detect bacterial contamination in real-time, using cutting edge nanotechnology and state of the art calibration techniques. The company's solution makes monitoring low-cost and easy to use with an IoT enabled dashboard and analytics tools.

AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

Verdex Technologies Inc. specializes in designing, patenting, and licensing non-toxic nanofiber production equipment for filtration and biomedical applications. The company’s innovative technology allows for the functionalization of nanofibers by incorporating nano-sized ingredients, which enhances the effectiveness of various products, including water filters that can eliminate challenging contaminants. Based in North Chesterfield, Virginia, Verdex Technologies emphasizes the use of biodegradable and bioresorbable polymers, avoiding harmful solvents and petroleum products in its processes. Founded by Rex B. Kirby, Jr., the company prides itself on its agile structure, integrity, and exceptional service, focusing on client needs and safety while maintaining high standards of quality. Verdex Technologies is financially robust, with substantial bonding capacity, positioning itself as a reliable partner in the nanofiber technology sector.

SyntheX, Inc. is a biotechnology company that focuses on drug discovery through a unique screening platform designed to identify and design therapeutics for oncology and other biotechnological applications. Founded in 2016 and based in San Francisco, SyntheX utilizes a synthetic biology-driven approach to efficiently synthesize and identify peptides and macrocycles that disrupt specific intracellular protein-protein interactions. The company’s development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating certain cancers that evade chemotherapy through homologous recombination. By leveraging genetically engineered circuits and proprietary DNA-encoded libraries, SyntheX targets drug discovery based on synthetic lethality and oncogene addiction, with an emphasis on addressing DNA damage repair and novel cell death mechanisms.

Nordetect IVS is a biochemical analysis company based in Copenhagen, Denmark, specializing in the development of biosensors and microfluidic chip technology for precision agriculture. Founded in 2016, the company focuses on nutrient analysis by detecting and quantifying essential macronutrients such as nitrogen, phosphorus, and potassium in soil. Its Lab-on-a-chip devices facilitate reliable and affordable nutrient testing, enabling agronomists and farm-service companies to deliver actionable insights to farmers regarding soil health. By providing results on the nutritional content of soil and recommendations for fertilizer application, Nordetect helps optimize crop performance and supports informed agricultural practices.

AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.

AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.

ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

Gaia Laboratories revolutionizes cell production, creating powerful solutions for the defining challenges of time. The founding principles behind Gaia Laboratories are to combat climate change, enable space-food, and make cell therapy accessible to everyone.

Developer of a real-time hydration biosensor platform designed to monitor human bodies at a molecular level. The company's platform is a wearable, non-invasive patch that captures an athlete's sweat and interprets key bio-markers in real-time, starting with electrolytes and total body fluid loss, enabling users to get personalized recommendations that help them improve their performance.

Our first product, HaloFilm turns any surface into an antimicrobial surface by holding chlorine from store-bought disinfectants on surfaces in a safe and effective manner for as long as a month. HaloFilm contains a novel polymer that when sprayed on creates a thin transparent film that binds to the surface and to chlorine, at levels equivalent to what you would find in a pool. Chlorine is a universally used as a disinfectant against bacteria, virus and fungi, but has a short effective life. We extend the lifetime and overall utility of chlorine to protect surfaces continuously. Our focus is on high touch surfaces in hospitals, mass transit systems, schools, and more; wherever pathogens spread and endanger human health.

Our first product, HaloFilm turns any surface into an antimicrobial surface by holding chlorine from store-bought disinfectants on surfaces in a safe and effective manner for as long as a month. HaloFilm contains a novel polymer that when sprayed on creates a thin transparent film that binds to the surface and to chlorine, at levels equivalent to what you would find in a pool. Chlorine is a universally used as a disinfectant against bacteria, virus and fungi, but has a short effective life. We extend the lifetime and overall utility of chlorine to protect surfaces continuously. Our focus is on high touch surfaces in hospitals, mass transit systems, schools, and more; wherever pathogens spread and endanger human health.